BPTS | Biophytis S.A.

Index- P/E- EPS (ttm)-15.33 Insider Own- Shs Outstand2.98M Perf Week-5.60%
Market Cap9.50M Forward P/E- EPS next Y- Insider Trans- Shs Float2.96M Perf Month-39.74%
Income-26.10M PEG- EPS next Q- Inst Own0.40% Short Float / Ratio1.08% / 0.81 Perf Quarter-56.99%
Sales- P/S- EPS this Y47.40% Inst Trans-83.97% Short Interest0.03M Perf Half Y-64.75%
Book/sh-1.00 P/B- EPS next Y- ROA-76.60% Target Price150.00 Perf Year-79.57%
Cash/sh3.12 P/C0.76 EPS next 5Y- ROE-748.00% 52W Range2.26 - 15.40 Perf YTD-40.02%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-84.61% Beta-
Dividend %- Quick Ratio1.00 Sales past 5Y- Gross Margin- 52W Low4.87% ATR0.30
Employees23 Current Ratio1.00 Sales Q/Q- Oper. Margin- RSI (14)37.56 Volatility3.85% 8.56%
OptionableNo Debt/Eq- EPS Q/Q95.90% Profit Margin- Rel Volume0.02 Prev Close2.38
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume39.62K Price2.37
Recom2.00 SMA20-13.68% SMA50-33.16% SMA200-54.15% Volume793 Change-0.42%
May-26-23 02:30AM
May-25-23 02:20AM
May-15-23 02:20AM
May-11-23 02:20AM
May-10-23 02:10PM
02:20AM Loading…
May-09-23 02:20AM
May-02-23 02:20AM
Apr-28-23 05:30PM
Apr-19-23 02:20AM
Apr-18-23 03:45AM
Mar-30-23 05:20PM
Mar-27-23 02:20AM
Mar-17-23 03:20AM
Mar-09-23 02:20AM
02:00AM Loading…
Mar-02-23 02:00AM
Feb-27-23 02:20AM
Feb-23-23 02:20AM
Feb-02-23 02:20AM
Jan-31-23 02:20AM
Jan-19-23 02:00AM
Jan-12-23 02:20AM
Jan-05-23 02:20AM
Dec-01-22 02:30AM
Nov-03-22 09:13AM
Oct-31-22 07:10PM
Oct-26-22 02:45AM
Sep-15-22 02:30AM
Sep-13-22 02:20AM
07:05AM Loading…
Sep-07-22 07:05AM
Jun-30-22 05:20PM
Jun-27-22 05:45PM
Jun-22-22 05:30PM
Jun-03-22 05:20PM
May-12-22 02:20AM
Apr-19-22 02:20AM
Apr-07-22 08:11AM
Apr-05-22 05:30PM
Mar-16-22 03:20AM
Feb-03-22 09:03AM
Dec-22-21 05:20PM
Dec-16-21 02:30AM
Nov-22-21 05:20PM
Nov-15-21 03:08PM
Oct-29-21 02:55AM
Oct-06-21 05:00PM
Oct-04-21 05:00PM
Sep-29-21 02:00AM
Sep-17-21 02:00AM
Sep-15-21 02:00AM
Sep-14-21 02:00AM
Sep-09-21 02:00AM
Aug-16-21 08:36AM
Aug-13-21 05:00PM
Aug-02-21 06:24AM
Jul-19-21 05:00PM
Jul-12-21 12:53PM
Jul-08-21 02:00AM
Jun-30-21 05:00PM
Jun-18-21 08:00PM
May-12-21 02:00AM
May-11-21 02:00AM
Apr-30-21 02:00AM
Apr-29-21 02:00AM
Apr-27-21 02:00AM
Apr-26-21 02:00AM
Apr-13-21 05:00PM
Mar-22-21 03:00AM
Mar-19-21 06:00PM
Mar-10-21 10:08PM
Feb-26-21 02:00AM
Feb-17-21 02:00AM
Feb-15-21 02:00AM
Feb-10-21 09:16AM
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.